Enveda's $311M Caps a Year of AI Drug Discovery Megarounds

On September 23, two AI drug discovery companies raised a combined $451 million. Enveda Biosciences closed a $311 million Series E, and Basecamp Research closed a $140 million Series C. Neither has a drug on the market. Enveda has three candidates in human testing. Basecamp's programs are preclinical. Investors paid anyway, and that is now the pattern rather than the exception.

BioPharma Dive counts at least 12 AI biotech companies that have raised venture rounds of $100 million or more since January 2024. Two of the three largest biotech rounds of 2026 went to AI drug discovery startups. The biggest by far was Isomorphic Labs' $2.1 billion Series B in May. The question the week's deals raise is not whether AI biotech can attract capital. It is what that capital is buying.

Enveda: chemistry from nature, priced like an IPO

Enveda, based in Colorado, uses AI to find molecules in living organisms such as plants and microbes, predict their structures and functions, and rank them by drug potential. Its Series E was led by Catalio Capital Management, with Surveyor Capital, T. Rowe Price, Lux Capital and a sovereign wealth fund among 17 investors, per BioPharma Dive. The company had already raised more than $530 million, including a $150 million Series D in 2025.

BioPharma Dive notes the $311 million rivals the totals raised in some of the sector's larger IPOs this year. That is the point worth sitting with. A private round of that size, with a public-markets investor like T. Rowe Price in the syndicate, is a crossover round in all but name.

The pipeline is real but young. ENV-294 is in a Phase 1b/2 study in atopic dermatitis and asthma. ENV-308 is in Phase 1 for obesity and weight maintenance. ENV-6949 is in Phase 1 for inflammatory bowel disease, working through the TL1A pathway. CEO Viswa Colluru made the case for the bet in plain terms: "the thing that moves the needle for patients and seeds power law returns for companies is first-in-class mechanisms."

Basecamp: a foundation model for the body

Basecamp Research, based in London, is making a different wager. Its Series C was led by S32, the fund affiliated with Bill Maris, with Nvidia, the NATO Innovation Fund and the Anthology Fund, a joint vehicle of Anthropic and Menlo Ventures, among more than a dozen investors, per SiliconANGLE.

The company's product is EDEN, a 28 billion parameter biological foundation model trained on the Trillion Gene Atlas, a dataset of more than 100 billion genes that Basecamp built with Anthropic, Nvidia and other partners. Basecamp is aiming EDEN at in vivo cell therapy, reprogramming a patient's cells inside the body by inserting DNA with large serine recombinases, enzymes drawn from bacteriophages. CEO Glen Gowers put it this way: "We design the models and the medicines to teach it how."

That is a model-first company raising drug-company money. Basecamp says the capital goes to clinical development and to pharma partnerships to commercialize the work.

The wave behind them

The two rounds sit on top of a year of larger ones. Isomorphic Labs, the Alphabet spinout run by Demis Hassabis, raised $2.1 billion in May in a round led by Thrive Capital, with Alphabet, GV, MGX, Temasek, CapitalG and the UK Sovereign AI Fund. Endpoints News ranked it the second largest biotech fundraise ever, behind Altos Labs. Isomorphic counts Novartis, Lilly and Johnson & Johnson as partners and says the money will push its programs toward the clinic.

In July, Chai Discovery raised $400 million at a $3.8 billion valuation in a Series C led by Index Ventures, roughly tripling the $1.3 billion valuation of its Series B seven months earlier. Chai sells molecule design models, including Chai-3, and has paid deployments with Lilly, Pfizer and Novartis.

In March, Earendil Labs, which is incorporated in Delaware and runs offices in Beijing, raised $787 million, with Sanofi among the backers. Sanofi had already signed two collaborations with the company, worth close to $2 billion combined in potential payouts. Earendil has nearly 20 drugs in development and one biologic for inflammatory bowel disease in Phase 1.

A Silicon Valley Bank executive, quoted by BioPharma Dive, summed up the market: the promise of AI drug design and protein modeling "is drawing staggering amounts of money."

What investors are actually buying

Read the rounds together and a split appears. Isomorphic, Chai and Basecamp are funded largely on the strength of their models and platforms, with pharma partnerships as the proof. Enveda and Earendil are funded more like classic biotechs, on the strength of clinical assets that happen to come from AI engines.

Both groups share one exposure: very little of this capital has been tested against late-stage clinical data. BioPharma Dive frames the haul against pipelines that remain early. The industry has its own caution on file: Verge Genomics, an earlier AI drug discovery company, rebranded its ambitions after a clinical trial failure, per BioPharma Dive.

What is different now is who is writing the checks. Sovereign funds, large crossover investors, Nvidia and Anthropic's fund are not traditional biotech specialists. Their participation reads as a bet on AI as a platform for science, with drug discovery as the clearest place to express it.

Why it matters

AI drug discovery has become one of the most heavily funded applications of AI outside the model labs, with at least 12 rounds of $100 million or more since 2024. That concentration raises the stakes on a handful of readouts. Enveda's Phase 1b/2 eczema data, Earendil's IBD program and Isomorphic's first entry into the clinic will be read as verdicts on the whole category, not just on individual companies. If they land, the megarounds will look cheap and the next wave will be larger. If they stumble, the sector will learn again that computing a molecule and proving a medicine are different problems, and the capital that arrived this fast can leave the same way.